Trajectory-Informed Breathomics for Dynamic Mapping of Health and Disease: Toward a *Health Navigation Framework*

Kenta T. Suzuki[1,2], Atsuhiro Nagasaki[3,4], Shinnichi Sakamoto[3,5], Kazuhisa Ouhara[6], Hideyuki Hyogo[7], Hiroshi Aikata[8], Toshinobu Takemoto[9], Akiko Tanaka[10], Goro Funakoshi[11], Yutaro Koyama[12], Kazushi Ikeda[1,2], Woosuck Shin[13], Kazuo Sato[10], Takashi Takata[14], Yuichi Sakumura[1,2,*], Mutsumi Miyauchi[3,*]

Graduate School of Science and Technology, Nara Institute of Science and Technology, Nara, Japan
Data Science Center, Nara Institute of Science and Technology, Nara, Japan
Department of Oral and Maxillofacial Pathobiology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan
Division of Molecular and Regenerative Prosthodontics, Tohoku University Graduate School of Dentistry, Miyagi, Japan
Division of Oral Pathology, Department of Diagnostic and Therapeutic Sciences, Meikai University School of Dentistry, Chiba, Japan
Department of Periodontology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan
Life Care Clinic Hiroshima, Hiroshima, Japan
Department of Gastroenterology, Hiroshima Prefectural Hospital, Hiroshima, Japan
Department of Oral Health Management, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan
Graduate School of Engineering, Aichi Institute of Technology, Aichi, Japan
Aichi Center for Industry and Science Technology, Aichi, Japan
Aichi Prefectural University, Aichi, Japan
National Institute of Advanced Industrial Science and Technology (AIST), Aichi, Japan
Shunan University, Yamaguchi, Japan

* Corresponding authors: Yuichi Sakumura (saku@bs.naist.jp) and Mutsumi Miyauchi (mmiya@hiroshima-u.ac.jp)

ABSTRACT

Background
Most diagnostic frameworks treat disease as static, overlooking its inherently dynamic and continuous progression. Noninvasive biomarkers capable of capturing physiological trajectories are critically needed for proactive health management.

Methods
We developed a breath-based health navigation framework using exhaled volatile organic compounds (VOCs) as integrative, real-time indicators of systemic metabolism and immunity. Breath profiles were collected from healthy individuals and patients with nonalcoholic steatohepatitis (NASH, recently redefined as metabolic dysfunction–associated steatohepatitis, MASH), hepatocellular carcinoma (HCC), and periodontitis (PD). Multidimensional analysis and trajectory-informed mapping were applied to project individual health states into a low-dimensional physiological space.

Results
Ratio-normalized VOC profiles revealed disease-specific metabolic signatures across P450-derived and microbiota-derived compounds. Machine learning achieved high diagnostic accuracy for distinguishing health, NASH, HCC, and PD, while dimensionality reduction and topological analysis visualized a continuous progression from health to advanced liver disease. This approach captured preclinical shifts and transitional states often missed by static diagnostics.

Conclusions

Exhaled VOCs can serve as dynamic biomarkers for mapping health–disease transitions. By offering clinicians an intuitive map to locate patients within the health–disease continuum and anticipate their trajectories, this framework enables proactive decision-making and personalized intervention strategies. Collectively, our work points toward a paradigm shift in disease monitoring, with future integration into portable sensing technologies for noninvasive, continuous health-state assessment.

Keywords: Volatile organic compounds (VOCs); health–disease continuum; physiological state mapping; metabolic dysfunction-associated steatohepatitis (MASH); noninvasive diagnostics; trajectory analysis

INTRODUCTION

Modern diagnostic frameworks in medicine remain largely dependent on static, categorical classifications of disease, often overlooking the inherently dynamic and continuous nature of physiological deterioration [1]. This structural limitation hinders timely intervention and prevention, especially in the context of chronic diseases [2], by obscuring early, subclinical transitions.

Metabolic dysfunction-associated steatotic liver disease (MASLD) exemplifies such challenges. MASLD arises in association with obesity, type 2 diabetes, and other metabolic disorders, progressing from simple steatosis to metabolic dysfunction–associated steatohepatitis (MASH; formerly termed nonalcoholic steatohepatitis, NASH), fibrosis, cirrhosis, and ultimately hepatocellular carcinoma (HCC) in a multi-stage manner [3-5]. This disease trajectory is influenced not only by hepatic metabolic dysfunction but also by gut microbiota alterations [6], the gut-liver axis, and systemic inflammatory conditions such as periodontitis [7], operating through metabolic–immune–microbiome crosstalk. MASLD thus represents a networked, multi-organ pathology that resists adequate characterization by static snapshots of single-organ function [8].

Current diagnostic tools, including blood tests, imaging, and molecular markers, are often based on single time-point measurements and lack the temporal resolution to capture subtle physiological transitions [9]. In contrast, volatile organic compounds (VOCs) in exhaled breath offer a portable, noninvasive, real-time window into systems-level metabolism. VOCs are generated through endogenous metabolic and detoxification processes involving the liver, gut microbiota, kidneys, immune system, and other organs, and are excreted via the lungs [10,11]. Breath VOCs are particularly informative in liver diseases, where specific ingerprints of aldehydes, ketones, and short-chain fatty acids have been shown to correlate with disease state [12,13] and may anticipate clinical change. These compounds often capture complex, multisystem perturbations that are inaccessible via blood or urine biomarkers [11,14], including cross-organ interactions.

Recent studies have demonstrated the potential of breath VOCs in diagnosing liver diseases such as cirrhosis or MASLD, often using classification models to distinguish disease from health [13-15]. Yet, such binary, snapshot-based approaches do not address the more fundamental question of how physiological states evolve over time. They offer no information about directionality, transitional states, or pre-symptomatic trajectories or early warning signals.

Here, we propose a time-resolved *health navigation model* that maps individual VOC profiles— collected from healthy controls, patients with MASH, HCC, and periodontitis—into a topologically coherent two-dimensional metabolic state space. Using time-series data, this model visualizes physiological transitions as directional velocity vectors. Inspired by RNA velocity approaches [16,17], we adapt the notion of state-specific kinetics to VOCs dynamics so that the framework captures not only the position of an individual within the health-disease continuum but also the trajectory and momentum of physiological change.

This dynamic mapping system is envisioned not as a mere classification tool; it is designed to serve clinicians as an intuitive visual interface that reveals in near real time whether a patient is approaching or moving away from a specific disease state. In principle, such a framework could allow early detection of presymptomatic micro-transitions in physiological state—often preceding clinical symptoms or lab abnormalities—and may ultimately support personalized decisions about when to intervene.

Looking ahead, integration with simplified, real-time breath VOCs sensing devices could enable longitudinal, at-home monitoring in everyday environments, delivering actionable trajectory feedback to individuals and establishing a foundation for proactive, individualized health management.

RESULTS

Ratio-based VOC profiles reveal disease-specific metabolic signatures

Interindividual variability in exhaled VOC concentrations arises from several factors, including age, sex, smoking habits, and pulmonary filtering capacity. As shown in **Table 1,** the participants in this study—exclusively Japanese—displayed heterogeneous backgrounds, including differences in age

and smoking status. While weak correlations were observed between some VOCs (such as o-xylene
and p-xylene) and age (**Table S4**), these compounds exhibited low concentrations across all
nonhealthy groups and did not display age-dependent trends within the healthy group (**Figure S1A**,
S1B). Moreover, a summative analysis of 16 VOCs indicated a general decline in VOC levels with
age and disease (**Figure S2A**, **S2B**), but considerable variation remained even among healthy
participants. These findings underscore the necessity of normalizing VOC data to minimize the
influence of lung function and individual variability.
136
To account for these confounding effects, we applied ratio-based normalization to the 16 VOC
concentrations in each sample (see **Methods**). To interpret these normalized VOC profiles in relation
to underlying pathophysiology, we categorized the 16 VOCs into three biologically meaningful
groups: cytochrome P450-metabolized compounds (P450), gut microbiota-derived compounds (Gut),
and other compounds (Others), as summarized in **Table 2**. This categorization allowed us to examine
disease-associated trends at the functional group level (**Figure 1A–C**).
143
In healthy individuals, the relative abundance of P450 and gut-derived VOCs was generally low,
whereas these categories exhibited marked elevation in NASH and HCC samples. Among the 16
VOCs, no single compound served as a robust biomarker; however, disease-specific signatures
appeared at the category level. Strikingly, xylene showed an opposite trend, with lower ratios in
disease groups, reinforcing the importance of combinatorial assessment rather than reliance on
individual VOCs. Moreover, acetic acid and acetoin showed opposite trends between NASH and
HCC, while toluene and p-xylene also contributed to disease-specific patterns, especially in
periodontitis (**Figure 1**).
152
To evaluate whether these category-based VOC ratios could differentiate health status, we
constructed diagnostic models using supervised machine learning (see **Methods**). We tested three
combinations of VOC categories: P450 alone, P450 plus gut-derived VOCs, and all three categories
combined (**Figure 3**). As shown in **Figure 2** and **Table 2**, P450 VOCs alone achieved high
classification accuracy, which improved upon inclusion of the gut-derived category (P450 + Gut).
The addition of the third category (Others) offered no significant performance gain, suggesting that
liver and gut-derived VOCs are the most informative. These results align with known
pathophysiological changes in liver disease, such as cytochrome P450 dysfunction and altered gut
flora [6]. The stepwise improvement in classification performance when including Gut VOCs along
with P450 VOCs was further validated in **Figure 2**, which illustrates the incremental contribution of
each category to diagnostic accuracy.
164
165 Importantly, omitting the ratio normalization step led to a marked decline in diagnostic performance
166 (**Figure S3**), confirming its critical role in extracting meaningful disease-related information. The
167 detailed composition and distribution of these optimal VOC combinations are shown in **Figure S4**.
168
169 Together, these findings demonstrate that the combined use of VOC ratio normalization and
170 functional categorization reveals disease-specific metabolic alterations. Rather than focusing on
171 absolute concentrations or individual compounds, our results highlight the diagnostic value of
172 category-level VOC patterns and establish a foundation for dynamic mapping of health–disease
173 trajectories in subsequent analyses.
174
175
Mapping health–disease transitions using exhaled VOCs

To move beyond binary classifications of "healthy" and "unhealthy," we examined whether VOC
profiles could support disease-resolved differentiation. While the high diagnostic accuracy achieved
for each group (**Figure 2**, **Table 3**) suggests that VOCs encode meaningful health information, it
remained unclear whether these patterns were disease-specific or simply reflected a general shift
away from health. To address this, we analyzed the distribution of VOC ratios across multiple
disease classes.
183
We first confirmed that several VOCs displayed disease-specific signatures (**Figure 1**, **Table S6,**
Figure S5). For example, acetic acid and acetoin exhibited inverse trends in NASH and HCC, while
p-xylene and toluene contributed distinctly to PD versus NASH classification. These patterns were
not apparent in raw concentration data but emerged clearly after ratio normalization. Such
compositional contrasts provided the molecular basis for moving from binary to multi-class
discrimination.

To further validate the disease specificity of VOC profiles, we also performed binary classification
between each disease and the healthy control group. As shown in **Figure 3**, optimal VOC
combinations using support vector machine (SVM) classifiers enabled highly accurate
discrimination of NASH (96.4%), HCC (96.4%), and PD (93.1%) from healthy individuals. These
results confirm that disease-associated shifts in VOC profiles are not only detectable but also
diagnostically meaningful, particularly for liver-related conditions.

Using random forest models and exhaustive feature selection (wrapper method), we identified an
optimal combination of 14 VOC ratios that achieved an overall classification accuracy of 80.1%
(234/292) across four classes: healthy, NASH, HCC, and PD (**Figure 4**). Given the small sample size
for PD, misclassifications tended to assign PD patients to either healthy or liver disease groups.
However, when restricted to the three major classes (healthy, NASH, and HCC), sensitivities
consistently exceeded 80%.

Beyond classification, our primary objective was to visualize physiological transitions across disease
states in a data-driven manner. To this end, we applied Uniform Manifold Approximation and
Projection (UMAP) for dimensionality reduction and Partition-Based Graph Abstraction (PAGA)
for topological trajectory analysis (**Figure 5**). The resulting two-dimensional map revealed distinct
clusters corresponding to different health conditions. Healthy and PD samples were located at one
end of the map, whereas HCC samples occupied the opposite side. NASH cases were broadly
distributed between these two poles, suggesting a continuous trajectory from health to severe liver
disease.

Importantly, these clusters preserved the topology of health states inferred from VOC composition,
implying that spatial proximity and vector directionality in the two-dimensional map reflect
underlying physiological transitions. This trajectory-informed map establishes a proof-of-concept
health navigation framework—a visual interface for locating an individual within the health–disease
continuum and anticipating the direction of physiological change.

219
220
221

DISCUSSION

Mapping Dynamic Health–Disease Transitions with Exhaled VOCs

Physiological states—including those of ostensibly healthy individuals—are not fixed but
continuously drift along a multidimensional continuum [1,2]. The direction and magnitude of these
changes are often state-dependent and influenced by multiple overlapping biological processes.
Capturing such transitions requires biomarkers that are not only sensitive and integrative but also
amenable to frequent, noninvasive measurement. If such biomarkers could be mapped to reflect both
current position and future trajectory within the health–disease landscape, they would provide a
transformative tool for screening, monitoring, and clinical decision-making.

In this study, we demonstrate that exhaled VOCs—traditionally used in isolated disease contexts
[15,18]—can serve a broader purpose when their compositional VOC profiles are analyzed in aggregate
and normalized for interindividual variability. We propose a novel strategy to reduce confounding
due to pulmonary function by preprocessing VOC concentrations into relative ratios. This
normalization unlocked hidden disease-related structure, revealing category-level signatures that
supported not only binary classification but also multi-class differentiation and trajectory
visualization [19].

To construct a low-dimensional representation of this physiological landscape, we applied UMAP
and PAGA—techniques originally developed to infer transcriptional trajectories in single-cell
genomics[16,17]. When applied to our VOC data, these methods revealed a spatially ordered
progression from healthy controls to NASH and finally to HCC (**Figure 5A**). The organization of
PAGA nodes and edges further suggested substructures, possibly corresponding to distinct HCC
etiologies, including metabolic (e.g., NASH) and viral origins (e.g., hepatitis B virus (HBV) or
hepatitis C virus (HCV)) (**Figure 5B**). Thus, the topology of exhaled VOCs encodes not only
diagnostic categories but also latent pathways of disease progression.
248

The high diagnostic performance achieved in this study—compared to prior reports [20]—was
attributable to two key factors: the high detection rate of our VOC panel (**Table S1**), and our data
preprocessing strategy based on ratio transformation. Certain compounds, such as butyric acid, were
excluded from classification due to low detection frequency and information content, a critical step
to avoid noise in predictive models [21]. Without this ratio-based normalization, classification
accuracy declined markedly (**Figure S3**), underscoring the importance of preprocessing. Although
deep learning offers powerful alternatives for automated feature extraction, its prohibitive sample
size requirements in clinical studies highlight the practical value of ratio-based approaches [11].

Although we focused on NASH and HCC in this analysis, the same approach could be extended to
visualize transitions involving other diseases that share metabolic or inflammatory pathways. The
VOC-derived coordinate space, once projected into a low-dimensional map, enables intuitive
interpretation of patient trajectories across diverse disease states. Crucially, this method requires only
breath samples and is compatible with real-time, continuous monitoring. This opens opportunities
for applications where repeated blood sampling is impractical—such as intensive care, neonatal
monitoring, and long-term at-home management.

Finally, unlike many previous studies that used VOCs primarily for classification without addressing
underlying biological mechanisms [18], our approach provides a mechanistic rationale. The
diagnostically informative VOCs identified here are metabolically linked to cytochrome P450
activity and microbial fermentation in the gut—two major systems implicated in chronic disease
progression [6,22]. In this sense, exhaled VOCs emerge not only as convenient diagnostic readouts but
as dynamic windows into the integrative metabolic state of the body.

Mechanistic Insights into Diagnostic Breath Biomarkers

To elucidate the biological underpinnings of the diagnostically informative VOCs identified in this
study, we categorized them into three classes based on metabolic origin: P450-metabolized
exogenous compounds, gut bacteria-derived metabolites, and other compounds (**Table 3**). Our
results showed that combining VOCs across these categories substantially improved diagnostic
accuracy for liver-related diseases (**Figure 2**). This integrative perspective highlights how multiple
organ systems jointly shape the breath metabolome. Below, we examine the possible physiological
mechanisms that may underlie VOC variations across different disease states.

P450-metabolized VOCs

Several P450-metabolized compounds—including toluene, limonene, styrene, and xylene—were
found to be useful in differentiating health states (**Table S6**, **Figure S5**). In particular, xylene
concentrations were markedly lower in NASH and HCC samples compared to healthy controls and
PD patients (**Figure 1A**). This depletion is consistent with impaired hepatic metabolism and
clearance capacity, which redistributes the relative balance of exhaled VOCs. Xylene is metabolized
in the liver into methylhippuric acid, a process modulated by toluene and other substrates competing
for P450 enzymes [23,24]. Disruption of this metabolic balance may thus explain the altered xylene
levels observed. Furthermore, elevated toluene levels have been reported in patients with various
cancers, including lung cancer [25], suggesting that dysregulated P450 metabolism may be a shared
signature of malignancy. Although causal pathways remain unresolved, the consistent involvement
of P450-related VOCs supports their potential as indirect markers of hepatic enzymatic activity.
Given that cytochrome P450 expression is implicated in both liver disease progression and
oncogenesis [26], these VOCs may represent accessible proxies of metabolic vulnerability.

Gut microbiota-derived VOCs

We also observed disease-dependent differences of VOCs originating from gut microbial
fermentation. Acetic acid and acetoin, in particular, varied across disease groups (**Figure 1**) and
contributed strongly to HCC versus NASH classification (**Table S6**, **Figure S5**). Increased acetic
acid in HCC patients may result from impaired hepatic clearance [27], whereas NASH patients may
show elevated levels due to subclinical microbial ethanol production and subsequent metabolism
[28,29]. Acetoin, a microbial metabolite enriched in tumor microenvironments but scarce in healthy
tissues [30], was especially useful in distinguishing HCC from NASH and PD. This tumor-associated
specificity suggests that acetoin in exhaled breath could serve as a noninvasive prognostic marker for
malignant transformation in NASH patients [31]. While other bacterial VOCs such as butyric and

propionic acid were not retained in the final model (**Table S5**), they may still hold relevance in
broader disease contexts not examined here.
308

Periodontitis-related mechanisms

Although PD is not a hepatic disorder, its inclusion provided insights into systemic disease
interactions. VOCs associated with both P450 metabolism and gut microbiota contributed to PD
classification (**Figure 2**). This aligns with prior evidence that chronic periodontal inflammation
perturbs gut–liver axis and contributes to systemic diseases including diabetes and fatty liver [32].
Periodontitis can disseminate bacteria, lipopolysaccharides, and cytokines into circulation, triggering
hepatic inflammation and fibrosis [33]. However, VOCs detected in deep lung exhalation are unlikely
to originate directly from oral pathogens; rather, they represent systemically filtered metabolic
products, distinct from volatile sulfides measured in oral headspace [34]. Despite this limitation, we
found that deep-lung VOC profiles enabled high diagnostic accuracy not only for PD but also for
comorbidity detection (**Figure 2**, **Table 3**), underscoring their potential as holistic biomarkers of
multi-organ crosstalk.
321

Limitations and Future Directions
323 While this study demonstrates the diagnostic potential of exhaled VOCs and their utility in mapping
324 physiological transitions, several limitations must be considered when interpreting the findings.
325

First, although we selected VOC combinations with the highest classification accuracy for each
disease (**Tables S5** and **S6**), some combinations yielded closely comparable performance, making it
difficult to determine whether the top-ranked sets were statistically superior. Additionally, certain
compounds—such as p-cymene, limonene, acetoin, hydrogen, dimethyl sulfide, methanethiol, and
nonanal—were associated with reduced classification accuracy for specific conditions like NASH
(**Figure 2**), despite their presence in some high-performing combinations. These discrepancies
suggest complex and possibly nonlinear relationships between individual VOCs and disease states.
However, the primary goal of this study was not to evaluate negative predictors, but to identify
configurations yielding high diagnostic accuracy. A more systematic evaluation of poorly performing
combinations would require larger sample sizes.
336

Second, although our sample size exceeded those of previous VOC-based diagnostic studies [20], it
remains insufficient for robust generalization, particularly for multigroup classification tasks
involving smaller cohorts such as PD. Moreover, the underlying etiology of HCC (e.g., viral
hepatitis vs. metabolic origin) could not be fully resolved owing to limited access to patient-level
metadata. This limits our ability to validate whether distinct clusters observed in the UMAP and
PAGA visualizations (**Figure 5**) reflect true etiological subtypes.
343

344 Third, diagnostic labels used in the machine learning pipeline were based on clinical diagnoses,
345 which are inherently uncertain. While large datasets may help average out misclassification noise,
346 future studies should consider incorporating longitudinal outcomes or biopsy-confirmed diagnoses to
347 strengthen ground-truth labeling.
348

Fourth, standardization and reproducibility remain technical challenges. VOC concentrations may
vary depending on instrument calibration, sensor type, and environmental factors. While we used
ratio transformation to correct for interindividual variability in lung function, additional
confounders—such as circadian rhythms, diet, medications, or age-related metabolic shifts—were
not fully controlled. Similarly, our findings are derived exclusively from Japanese participants,
whose gut microbiota and environmental exposures may differ significantly from other populations.
Broader validation across racially and geographically diverse cohorts is therefore essential.
Despite these limitations, this study lays the foundation for a novel diagnostic framework based on
breath analysis. The ability to project individuals—healthy and diseased—into a shared
physiological space using a noninvasive, real-time biomarker opens avenues for proactive and
longitudinal health monitoring. Once validated in larger and more diverse populations, this method
could ultimately enable not only early diagnosis but also personalized intervention planning.
361

While this study employed GC–MS for high-resolution VOC detection, real-world implementation
will require the development of portable, low-cost, and real-time sensing devices [11,35]. Advances in
compact semiconductor-based sensor arrays could enable widespread and on-demand VOC
measurement, eliminating the logistical barriers of centralized laboratory analysis. Integration of

such sensors into bedside monitors or wearable devices may transform this approach into a scalable
and accessible *health navigation framework*, deployable in both clinical and everyday environments.
368
369 Collectively, this work points toward a paradigm shift: from discrete, episodic diagnoses to
370 continuous, trajectory-informed navigation of health. Because everyone breathes, breathomics has
371 the potential to democratize access to ultra-early, preventive diagnostics—allowing deviation from
372 baseline health to be detected before symptoms arise, and ultimately contributing to reduced disease
373 burden and healthcare costs.
374

MATERIALS and METHODS

Data Source

Study Participants

Exhaled breath samples were collected following approval by the Ethics Committee of Hiroshima
University (approval number E-922). Written informed consent was obtained from all participants
prior to sample collection. The study enrolled 67 patients diagnosed with nonalcoholic
steatohepatitis (NASH), 95 patients with hepatocellular carcinoma (HCC), 29 patients with
periodontitis (PD), and 101 healthy control participants (Ctrl). Participants were selected randomly
and included only if they consented to participate. Given that diagnosis and enrollment occurred
prior to the recent adoption of the MASH terminology, we use NASH throughout.
385
386 Breath samples were anonymized by removing personally identifiable information and assigning
387 anonymized codes. Only non-identifiable demographic information, such as age and sex, was
388 retained for analysis. Disease severity and stage were not recorded; each sample was labeled with a
389 categorical disease group (NASH, HCC, PD, or Ctrl).
390

Definition of Disease Groups

At the time of data collection, NASH was diagnosed at the Department of Gastroenterology and
Metabolism, Hiroshima University Hospital, according to the Japanese Society of Hepatology
Guidelines [36]. Diagnostic criteria included: (i) hepatic steatosis on imaging, (ii) alcohol intake <30
g/day (men) or <20 g/day (women), (iii) exclusion of other hepatic pathologies, and histological
confirmation of steatohepatitis.
397
398 HCC was diagnosed according to the Japanese Society of Hepatology Guidelines for Hepatocellular
399 Carcinoma [37], based on either histological confirmation or characteristic imaging findings.
400 Underlying liver diseases in HCC patients included viral hepatitis (HBV or HCV), alcoholic liver
401 disease, and NASH.
402
403 PD was diagnosed based on criteria from the Japanese Society of Periodontology [38], defined by the
404 presence of periodontal pockets >4 mm with bleeding on probing, excluding cases of gingivitis.
405
406 The control group consisted of:
407
408 1.   Healthy university students with periodontal pockets ≤3 mm,
409 2.   Individuals with a history of periodontitis who had been successfully treated (current
410   pockets ≤3 mm),
411 3.   Individuals with pockets ≥4 mm but no bleeding,
412 4.   University residents and staff with normal liver function tests.
413
414 All collected samples were included in the final analysis without exclusion.
415

416 ### Breath Sampling and VOC Measurement

417 Exhaled breath and ambient air samples were collected at Hiroshima University Hospital (Hiroshima,
418 Japan) using 1 L polyvinylidene fluoride (PVDF) analytical barrier bags (Omi Odor-Air Service
419 Corp., Omihachiman, Japan). To account for environmental background VOCs, ambient air within
420 the sampling room was collected in parallel.
421

Prior to sample collection, participants were instructed to refrain from eating and smoking for at
least two hours. They were seated in the breath sampling room for at least 10 minutes to equilibrate
and breathe normally. Each participant then took two deep breaths, followed by a third deep breath
with a 20-second breath hold. Exhalation was performed gently over ~5 seconds into the barrier bag.
Breath samples were collected from all participants after they received standardized training on the
collection protocol. Personnel underwent supervised instruction and practiced until proficiency was
confirmed, ensuring methodological consistency.
429
430 VOC analyses were performed within 32 hours of collection at the Knowledge Hub Aichi (Aichi,
431 Japan). Two trained staff members conducted all collections for participants across all disease groups
432 (Ctrl, NASH, HCC, PD).
433

VOC Analysis via GC–MS

435 VOC detection was conducted using a GCMS-QP2010 Ultra system (Shimadzu Corporation, Kyoto,
436 Japan) equipped with a PY-3030D multifunctional pyrolysis unit (FRONTIER LAB, Fukushima,
437 Japan). A capillary column (Ultra ALLOY-1, 60 m $\times$ 0.25 mm ID $\times$ 1.0 μm df; FRONTIER LAB)
438 was employed for chromatographic separation.
439
440 Exhaled air from the PVDF bag was adsorbed onto TENAX TA or TENAX GR (GL Sciences Inc.,
441 Tokyo, Japan), then desorbed thermally using the PY-3030D system. Samples were cold-trapped
442 using liquid nitrogen and analyzed with helium (purity 99.99995%; Taiyo Nippon Sanso, Japan) as
443 the carrier gas. To eliminate ambient VOC contamination, background subtraction was performed
444 based on previous methodology [39].
445
446 Hydrogen gas was analyzed separately using a thermoelectric hydrogen sensor-based breath analyzer
447 [40,41], which incorporates a self-calibration feature and achieves ±2 ppm accuracy against a 200 ppm
448 hydrogen standard gas.
449
A total of 16 compounds—including hydrogen (non-VOC)—were selected for downstream analysis
based on high detection frequency across participants (**Table S1**). These compounds were
categorized into three groups: (1) P450-metabolized external compounds, (2) gut bacteria–derived
VOCs, and (3) other compounds, as defined in **Table 1**. The categorization was based on prior
biochemical and epidemiological literature [15,42]. Disease-specific associations of each compound are
provided in **Table S2**.
456
457

Analysis

Data Preprocessing

460 To address individual variability in exhaled VOC concentrations, we implemented a series of
461 preprocessing steps. As a surrogate for pulmonary filtering capacity, we calculated the linear sum of
462 all detected VOC concentrations. This approach leverages the law of large numbers to reduce
463 individual variability, providing a robust estimate of lung function.
464
However, absolute concentrations of VOCs can be influenced by non-disease-related factors,
potentially masking disease-specific signals. To mitigate this, we used relative concentration ratios
rather than raw concentrations. Specifically, we computed the ratio of each VOC to the total
concentration of VOCs that were deemed disease-relevant based on their diagnostic performance in
machine learning models. This approach enhances sensitivity to disease-specific changes while
minimizing noise from unrelated compounds.
471

Machine Learning–Based Classification

473 We employed supervised machine learning to classify participants by disease status using VOC
474 concentration ratios. For binary classification tasks (e.g., healthy vs. diseased or between disease
475 types), we used a nonlinear support vector machine (SVM) with a Gaussian kernel [43]. The kernel
476 width parameter (σ) and regularization parameter (C) were optimized via grid search to maximize
477 classification accuracy (**Table S3**).
478

479 For multiclass classification (healthy, NASH, HCC, and PD), we used random forest models [44],
480 which are well-suited for handling small- to medium-scale biomedical datasets. All analyses were
481 conducted in MATLAB (R2023a; Statistics and Machine Learning Toolbox, MathWorks).
482
483 To identify diagnostically informative VOC subsets, we employed a wrapper-based feature selection
484 method [45]. We calculated classification accuracy for all possible combinations of two or more VOCs
485 (excluding single-VOC models), resulting in a total of 65,319 evaluated subsets. These subsets were
486 also categorized by their VOC type as defined in **Table 2** (P450-related, gut bacteria–related, or
487 other), allowing for comparisons across biological pathways.

Accuracy Evaluation

489 Model performance was evaluated using 10-fold cross-validation [46]. For each iteration, the dataset
490 was split into 90% training and 10% testing sets. The testing outcomes were categorized as true
491 positives, true negatives, false positives, or false negatives. In binary classification tasks involving
492 disease pairs, the disease with the smaller sample size was defined as the positive class. The
493 training/test splits maintained the original ratio of healthy to diseased samples.
494
495 Performance metrics included classification accuracy, sensitivity, specificity, and the area under the
496 receiver operating characteristic curve for binary tasks. For multiclass (4-class) classification, overall
497 accuracy was reported and visualized using a confusion matrix.
498

Visualization of Disease Interrelationships

500 To visualize the relationships among disease groups, we used the VOC combination that yielded the
501 highest accuracy in 4-class classification. We first applied UMAP [47], a nonlinear dimensionality
502 reduction method that preserves the topological structure of the original high-dimensional data in
503 two dimensions. This enabled intuitive visualization of sample distribution across disease states.
504
505 Next, we applied PAGA [16], originally developed for single-cell transcriptomic analysis, to model
506 state transitions between health conditions. In the PAGA graph, nodes represent clusters of samples,
507 and edges represent similarity-based transitions between them.
508
509 To infer dynamic disease trajectories, we used CellRank [17], which estimates transition probabilities
510 based on a pseudotime kernel. Clustering was performed using the Leiden algorithm, and a starting
511 point ("root") was defined in the cluster containing healthy participants. Transition paths were
512 overlaid on the UMAP projection, illustrating plausible trajectories from health to various disease
513 states.
514

Statistical analysis

To examine potential confounding by age and smoking status [18], correlation ratio analyses were
conducted with VOC concentration as the dependent variable and age or smoking status (smoker vs.
non-smoker) as independent variables. Additionally, we used the Kruskal–Wallis test to assess
significant differences in diagnostic accuracy across VOC combinations identified via the wrapper
method. A p-value < 0.01 was considered statistically significant. All analyses were performed using
Python 3.8.
522
523

Abbreviations
Ctrl: Healthy control participants
GC☐MS: Gas chromatography–mass spectrometry
HBV: hepatitis B virus
HCC: Hepatocellular carcinoma
HCV: hepatitis C virus
MASH: Metabolic dysfunction-associated steatohepatitis
MASLD: Metabolic dysfunction-associated steatotic liver disease
NAFLD: Nonalcoholic fatty liver disease
NASH: Nonalcoholic steatohepatitis
PAGA : Partition-Based Graph Abstraction
PD: Periodontitis
PVDF: polyvinylidene fluoride

P450: Cytochrome P450
SVM: Support Vector Machine
UMAP: Uniform Manifold Approximation and Projection
VOCs: Volatile organic compounds
541
542

DECLARATIONS

Funding

This study was partially supported by the Development Project for Extremely Early Diagnostics Technologies for Human Diseases of Aichi Prefecture in Japan (K.S.; W.S.; Y.S.; M.M.), the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number 20H04283 (Y.S.), and the Japan Science and Technology Agency (JST) SPRING Grant Number JPMJSP2140 (K.T.S.).

Acknowledgements

The study team would like to sincerely thank all the participants. We thank Mr. H. Tokutake from Aichi Prefectural University, Professor J. Kato from Nara Institute of Science and Technology, and Dr. T. Itoh from the National Institute of Advanced Industrial Science and Technology (AIST) for their helpful discussions and technical comments.

AUTHOR CONTRIBUTIONS

Conceptualization, K.T.S., Y.S., and M.M.; Formal Analysis, G.F., A.T., Y.S., K.I., and K.T.S.; Funding Acquisition, K.T.S., W.S., K.S., Y.S., and M.M.; Investigation, K.O., S.S., A.N., T. Takemoto, and H.H.; Resources, K.O., W.S., T. Takemoto, H.A., and H.H.; Software Programming, K.T.S. and Y.K.; Supervision, Y.S., K.I., and M.M.; Writing – Original Draft Preparation, K.T.S., Y.S., and M.M.; Writing – Review & Editing, Y.S., M.M., K.T.S., K.I., W.S., A.N., S.S., H.A., H.H., K.S., and T. Takata.

COMPETING INTERESTS

All authors declare no financial or nonfinancial competing interests.

DATA AVAILABILITY

The datasets generated and/or analyzed during the current study are not publicly available in accordance with the ethical guidelines set by the Japanese government for medical and biological research involving human participants.

REFERENCES

1. Krahn, G. L. *et al.* It's time to reconsider how we define health: Perspective from
disability and chronic condition. *Disabil. Heal. J.* **14**, 101129 (2021).

2. Ziegler, L. E. & (HCSP), on behalf of the H. C. for P. H. AB1095 Early diagnosis
and treatment of chronic diseases: national review and guidelines - ra as an example.
Ann. Rheum. Dis. **76**, 1438 (2017).

3. Estes, C. *et al.* Modeling NAFLD disease burden in China, France, Germany, Italy,
Japan, Spain, United Kingdom, and United States for the period 2016–2030. *J Hepatol*
69, 896–904 (2018).

4. Phoolchund, A. G. S. & Khakoo, S. I. MASLD and the Development of HCC:
Pathogenesis and Therapeutic Challenges. *Cancers* **16**, 259 (2024).

5. Friedman, S. L. Fat, fibrosis, and the future: navigating the maze of MASLD/MASH.
J. Clin. Investig. **135**, e186418 (2025).

6. Kolodziejczyk, A. A., Zheng, D., Shibolet, O. & Elinav, E. The role of the
microbiome in NAFLD and NASH. *Embo Mol Med* **11**, e9302 (2019).

7. Arimatsu, K. *et al.* Oral pathobiont induces systemic inflammation and metabolic
changes associated with alteration of gut microbiota. *Sci. Rep.* **4**, 4828 (2014).

8. EASL, EASD & EASO. EASL–EASD–EASO clinical practice guidelines for the
management of non-alcoholic fatty liver disease. *J Hepatol* **64**, 1388–1402 (2016).

9. Myrkhiyeva, Z. *et al.* Dynamic measurement of a cancer biomarker: Towards in situ
application of a fiber-optic ball resonator biosensor in CD44 protein detection. *Sensors*
24, 1991 (2024).

10. Costello, B. de L. *et al.* A review of the volatiles from the healthy human body. *J.*
Breath Res. **8**, 014001 (2014).

11. Chou, H., Godbeer, L., Allsworth, M., Boyle, B. & Ball, M. L. Progress and
challenges of developing volatile metabolites from exhaled breath as a biomarker
platform. *Metabolomics* **20**, 72 (2024).

12. Dadamio, J. *et al.* Breath biomarkers of liver cirrhosis. *J Chromatogr B* **905**, 17–22
(2012).

13. Río, R. F. del *et al.* Volatile biomarkers in breath associated with liver cirrhosis —
comparisons of pre- and post-liver transplant breath samples. *Ebiomedicine* **2**, 1243–
1250 (2015).

14. Sinha, R. *et al.* Volatomic analysis identifies compounds that can stratify non-
alcoholic fatty liver disease. *Jhep Reports* **2**, 100137 (2020).

15. Stavropoulos, G. Exhaled breath analysis: the road towards its clinical
implementation. (2023) doi:10.26481/dis.20230525gs.

16. Wolf, F. A. *et al.* PAGA: graph abstraction reconciles clustering with trajectory
inference through a topology preserving map of single cells. *Genome Biol.* **20**, 59
(2019).

17. Lange, M. *et al.* CellRank for directed single-cell fate mapping. *Nat. Methods* **19**,
159–170 (2022).

18. Nakhleh, M. K. *et al.* Diagnosis and classification of 17 diseases from 1404 subjects
via pattern analysis of exhaled molecules. *Acs Nano* **11**, 112–125 (2017).

19. Gao, Y. *et al.* Volatile organic compounds in exhaled breath: Applications in cancer
diagnosis and predicting treatment efficacy. *Cancer Pathog. Ther.* (2025)
doi:10.1016/j.cpt.2024.12.004.

20. Stavropoulos, G. *et al.* Liver impairment—the potential application of volatile
organic compounds in hepatology. *Metabolites* **11**, 618 (2021).

21. Maniruzzaman, Md. *et al.* Accurate diabetes risk stratification using machine
learning: role of missing value and outliers. *J Med Syst* **42**, 92 (2018).

22. Kumar, A. R. *et al.* Impact of gut microbiota on metabolic dysfunction-associated
steatohepatitis and hepatocellular carcinoma: pathways, diagnostic opportunities and
therapeutic advances. *Eur. J. Méd. Res.* **29**, 485 (2024).

23. Tardif, R., Laparé, S., Krishnan, K. & Brodeur, J. A descriptive and mechanistic
study of the interaction between toluene and xylene in humans. *Int Arch Occ Env Hea*
65, S135–S137 (1993).

24. Dennison, J. E., Andersen, M. E., Clewell, H. J. & Yang, R. S. H. Development of a
physiologically based pharmacokinetic model for volatile fractions of gasoline using
chemical lumping analysis. *Environ Sci Technol* **38**, 5674–5681 (2004).

25. Oh, Y. *et al.* Olfactory detection of toluene by detection rats for potential screening
of lung cancer. *Sensors* **21**, 2967 (2021).

26. Li, M. *et al.* Gene polymorphism of cytochrome P450 significantly affects lung
cancer susceptibility. *Cancer Med.* **8**, 4892–4905 (2019).

27. Chen, S., Mahadevan, V. & Zieve, L. Volatile fatty acids in the breath of patients
with cirrhosis of the liver. *J Laboratory Clin Medicine* **75**, 622–7 (1970).

28. Jacobsen, E. The metabolism of ethyl alcohol. *Nature* **169**, 645–647 (1952).

29. Zhu, L. *et al.* Characterization of gut microbiomes in nonalcoholic steatohepatitis
(NASH) patients: a connection between endogenous alcohol and NASH. *Hepatology* **57**,
601–609 (2013).

30. Baggetto, L. G. & Lehninger, A. L. Formation and utilization of acetoin, an unusual
product of pyruvate metabolism by ehrlich and AS30-D tumor mitochondria. *J Biol*
Chem **262**, 9535–9541 (1987).

31. Kato, M. *et al.* Non-target GC–MS analyses of fecal VOCs in NASH-hepatocellular
carcinoma model STAM mice. *Sci. Rep.* **13**, 8924 (2023).

32. Kitamoto, S. *et al.* The intermucosal connection between the mouth and gut in
commensal pathobiont-driven colitis. *Cell* **182**, 447-462.e14 (2020).

33. Nagasaki, A. *et al.* Elimination of porphyromonas gingivalis inhibits liver fibrosis
and inflammation in NASH. *J Clin Periodontol* **48**, 1367–1378 (2021).

34. Zhang, T., Xue, Y., Chen, Y., Wan, H. & Wang, P. Research on intelligent
electronic nose based on exhaled breath to detect halitosis. *Ecs Meet Abstr* **MA2021-01**,
1348–1348 (2021).

35. Sadeghi, P., Alshawabkeh, R., Rui, A. & Sun, N. X. A comprehensive review of
biomarker sensors for a breathalyzer platform. *Sensors* **24**, 7263 (2024).

36. Watanabe, S. *et al.* Evidence-based clinical practice guidelines for nonalcoholic
fatty liver disease/nonalcoholic steatohepatitis. *J. Gastroenterol.* **50**, 364–377 (2015).

37. Kokudo, N. *et al.* Evidence☐based clinical practice guidelines for hepatocellular
carcinoma: The Japan society of hepatology 2013 update (3rd JSH☐HCC guidelines).
Hepatol. Res. **45**, (2015).

38. Periodontology, T. J. S. of. JSP clinical practice guideline for the periodontal
treatment, 2015. *The Japanese Society of Periodontology* (2015).

39. Itoh, T. *et al.* Development of an exhaled breath monitoring system with
semiconductive gas sensors, a gas condenser unit, and gas chromatograph columns.
Sensors **16**, 1891 (2016).

40. Shin, W. *et al.* Fabrication of thermoelectric gas sensors on micro-hotplates. *Sensors
Actuators B Chem* **139**, 340–345 (2009).

41. Sakai, D. *et al.* Increase in breath hydrogen concentration was correlated with the
main pancreatic duct stenosis. *J Breath Res* **12**, 036004 (2018).

42. Malderen, K. V., Winter, B. Y. D., Man, J. G. D., Schepper, H. U. D. & Lamote, K.
Volatomics in inflammatory bowel disease and irritable bowel syndrome. *EBioMedicine*
54, 102725 (2020).

43. Boser, B. E., Guyon, I. M. & Vapnik, V. N. A training algorithm for optimal margin
classifiers. *Proc Fifth Annu Work Comput Learn Theory - Colt '92* 144–152 (1992)
doi:10.1145/130385.130401.

44. Breiman, L. Random forests. *Mach Learn* **45**, 5–32 (2001).

45. Kohavi, Ron & Sommerfield, and D. Feature subset selection using the wrapper
method: overfitting and dynamic search space topology. *KDD* 192–197 (1995)
doi:10.5555/3001335.3001367.

46. Polat, K., Güneş, S. & Arslan, A. A cascade learning system for classification of
diabetes disease: Generalized discriminant analysis and least square support vector
machine. *Expert Syst Appl* **34**, 482–487 (2008).

47. McInnes, L., Healy, J. & Melville, J. UMAP: uniform manifold approximation and
projection for dimension reduction. *arXiv* (2018) doi:10.48550/arxiv.1802.03426.

685
686

TABLES

Table 1 Participant characteristics. N/A represents the number of participants who did not give their consent to provide information on age and sex; their data were thus treated as missing.

Disease	Sample	Age (years)	Smoking	Sex		
				Male	Female	N/A
Healthy	101	24.5±6.73	7	34	55	12
NASH	67	60.0±10.8	10	41	25	1
HCC	95	70.7±10.0	15	52	27	16
PD	29	67.8±11.5	4	11	18	0

Table 2 Categorization and breakdown of VOCs. P450-metabolized external components, bacterial gut components, and other components are abbreviated as P450. Gut, and Others, respectively.

Category	Description	VOC
P450	Metabolized by cytochrome P450 in the liver and related to liver function.	p-Cymene, Limonene, Styrene, Toluene, (m, o, p)-Xylene
Gut	Mainly produced by gut bacteria or reflecting gut activity.	Acetoin, Acetic acid, Butyric acid, Hydrogen[*], Propionic acid
Others	Identified in related studies.	Acetone, Dimethyl sulfide, Methanethiol, Nonanal

[*] Although hydrogen is not a VOC, it is included here as a metabolic product of gut bacteria.

Table 3 Means and standard errors of accuracy by category condition in Figure 2. The bolded values indicate the highest accuracy for each disease.

Category condition	NASH	HCC	PD
P450	0.85 ± 0.08	0.85 ± 0.08	0.81 ± 0.03
P450, Gut	**0.89 ± 0.06**	**0.88 ± 0.06**	0.83 ± 0.03
P450, Gut, Others	0.88 ± 0.06	0.88 ± 0.05	**0.84 ± 0.03**
P450, Others	0.84 ± 0.09	0.85 ± 0.07	0.81 ± 0.02
Gut	0.73 ± 0.06	0.74 ± 0.08	0.80 ± 0.02
Gut, Others	0.74 ± 0.06	0.77 ± 0.06	0.80 ± 0.02
Others	0.65 ± 0.06	0.64 ± 0.06	0.78 ± 0.01

FIGURE LEGENDS

Figure 1 Distribution of VOC ratios in healthy and diseased patients highlighting differences in P450, gut-derived VOCs, and other VOCs. (A) Distribution of the percentages of VOCs metabolized by P450. (B) Distribution of the ratios of VOCs derived from gut bacteria. (C) Distribution of the proportions of other VOCs. C, P, N, and H represent the control, PD, NASH, and HCC groups, respectively. The boxplots show the median and interquartile range. For each participant, all 16 VOC ratios were obtained by dividing each VOC concentration by the sum of all VOC concentrations (total VOCs). Abbreviations: Ctrl, Healthy control; HCC, Hepatocellular carcinoma; NASH, Nonalcoholic steatohepatitis; PD, Periodontitis; VOCs, Volatile organic compounds.

Figure 2 Accuracy of healthy vs. nonhealthy (i.e., disease) diagnoses for each combination of VOC categories. The horizontal axis represents the different combinations of VOC categories. Diagnostic accuracy was calculated for each combination using the corresponding set of VOCs. We employed ratios specific to selected VOCs (see Methods). For a single VOC category, the diagnostic accuracy is shown using only the VOCs within that category. Significance difference tests (†, Kruskal□Wallis test, significance level p = 0.01) were performed to compare the means among the three conditions on the left-hand side, and the results were significant for all three diagnoses. The mean values for diagnostic accuracy are provided in Error! Reference source not found., while **Suppl. Table 5** shows the maximum values for each precision group. Abbreviations: Gut, bacterial gut components; Others, components not included in P450 or the gut; P450, cytochrome P450-metabolized external components.

Figure 3 Diagnostic performance when using combinations of VOCs with the highest accuracy.

Each confusion matrix demonstrates the diagnostic performance for (**A**) NASH, (**B**) HCC, and (**C**)
PD patients relative to healthy controls. The rows denote the actual class, while the columns
represent the predicted class. Diagonal elements represent correctly classified instances, whereas off-
diagonal elements signify misclassified instances. The values in the title, top left, and bottom right
represent accuracy, specificity, and sensitivity, respectively.
Abbreviations: Ctrl, Healthy control; HCC, Hepatocellular carcinoma; N, healthy; NASH,
Nonalcoholic steatohepatitis; P, disease; PD, Periodontitis.
737
738   **Figure 4 Four-class classification of healthy controls and patients with three diseases.** The
739   vertical axis shows the ground truth, indicating the true conditions, and the horizontal axis shows the
740   conditions predicted by random forest classification.
741
Figure 5 Visualization of disease transitions. (**A**) UMAP; for the 14 combinations of VOCs for
which the highest accuracy was obtained in the random forest classification, the high-dimensional
data were compressed to two dimensions using UMAP, a dimensionality reduction method. The data
points belonging to the same cluster are plotted in close proximity. In the resulting embedding space,
clusters were visualized using PAGA. The relationships between clusters are visualized as nodes and
edges. Edges with weights greater than 0.55 remained. Green dots indicate healthy participants, blue
dots indicate periodontitis patients, orange dots indicate NASH patients, purple dots indicate HCC
patients, and white circles indicate nodes of PAGA-treated patients. (**B**) UMAP embedding with
PAGA overlay. The same UMAP embedding is shown with a partition-based graph abstraction
(PAGA) graph overlay, where PAGA represents the transition relationships between clusters depicted
as nodes and edges. The pie charts overlaid on the nodes show the percentages of different classes
within each cluster. Edges between nodes indicate the strength of connections between clusters, with
thicker edges indicating stronger connections. The direction of the edges indicates the estimated
direction of cellular transitions. Abbreviations: Ctrl, Healthy control; HCC, Hepatocellular
carcinoma; NASH, Nonalcoholic steatohepatitis; PAGA, Partition-Based Graph Abstraction; PD,
Periodontitis, UMAP, Uniform Manifold Approximation and Projection.
758

Figures

Figure 1 Distribution of VOC ratios in healthy and diseased patients highlighting differences in P450, gut-derived VOCs, and other VOCs

Figure 2 Accuracy of healthy vs. nonhealthy (i.e., disease) diagnoses for each combination of VOC categories.

776
777 **Figure 3 Diagnostic performance when using combinations of VOCs with the highest accuracy.**
778
779
780

782
783 **Figure 4 Four-class classification of healthy controls and patients with three diseases.**
784
785

787
788 **Figure 5 Visualization of disease transitions.**